Mirtazapine: Nursing Drug Guide, Sedation & Falls & NCLEX Review
Bedtime mirtazapine can sedate before mood improves—pair every evening dose with orthostatic checks, fall precautions, and a clear serotonergic medication list so stacked antidepressants do not trigger serotonin syndrome in vulnerable adults.
Sedation plus orthostatic hypotension can cause next-day impairment and falls—especially in older adults—while serotonin syndrome risk rises with MAO inhibitors (including linezolid), SSRIs, SNRIs, tramadol, and other serotonergic drugs. Labeling carries a boxed warning for increased suicidal thinking and behavior in pediatric and young adult patients; mirtazapine is not approved in pediatric patients. Monitor all patients at initiation and dose changes for worsening depression, suicidality, and agitation. Stop therapy and evaluate for agranulocytosis if sore throat, fever, or stomatitis occurs with a low white blood cell count. Wait at least 14 days between MAOI and mirtazapine therapy per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Give mirtazapine at bedtime, then reassess sedation, orthostatics, and mood at every contact during the first weeks and after each titration. Reconcile serotonergic drugs before every dose, hold for MAOI overlap or infection with low WBC, and escalate agitation, hyperreflexia, or fever immediately—do not assume early sleepiness means the depression is improving.
Most common brand names
Mirtazapine is available as oral film-coated tablets (commonly 15 mg and 30 mg; some products include 45 mg) and as orally disintegrating tablets (brand Remeron SolTab). The legacy brand Remeron and multiple generics are used in inpatient and community settings—always verify strength on the label and MAR.
Tablets may be scored for splitting only when the prescriber and pharmacy approve; do not crush or split orally disintegrating formulations unless directed by pharmacy.
Why we give it — Indications
FDA-approved labeling for mirtazapine tablets is major depressive disorder (MDD) in adults. Nurses also see off-label use for insomnia, poor appetite, or anxiety with depression—apply the same sedation, fall, and serotonergic interaction precautions whenever the drug is ordered.
| Use | Detail |
|---|---|
| Major depressive disorder (labeled) | Oral tablets once daily, preferably at bedtime; antidepressant effect may take 1 to 2 weeks or longer—sedation often appears earlier |
| Sleep or appetite support (common off-label) | Evening dosing used when insomnia or weight loss accompanies depression—monitor for oversedation and metabolic changes |
| Pediatric MDD | Not approved in pediatric patients per labeling; boxed suicidality warning applies to antidepressants in young patients |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Mirtazapine is a tetracyclic antidepressant. Prescribing information states the mechanism for MDD treatment is unclear, but efficacy may involve antagonism at central presynaptic α2-adrenergic receptors, increasing noradrenergic and serotonergic activity. It also antagonizes histamine H1, peripheral α1-adrenergic, and muscarinic receptors—explaining prominent somnolence, orthostatic hypotension, and anticholinergic-type effects (dry mouth, constipation). Unlike many SSRIs, it does not significantly inhibit serotonin reuptake, but serotonin syndrome can still occur alone or with other serotonergic drugs.
Dosing overview
Start low in older adults and in renal or hepatic impairment. Increase only after 1 to 2 weeks at each dose level so response can be evaluated.
Discontinuation: Taper gradually when stopping—abrupt cessation can cause dizziness, abnormal dreams, anxiety, nausea, and other discontinuation symptoms per labeling.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact prescriber or pharmacist if multiple doses are missed, especially after dose increases.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (sedation) | Somnolence common early; may precede mood benefit | Do not assume sedation equals full antidepressant response |
| Antidepressant effect | May take 1 to 2 weeks or longer for adequate response per labeling | Continue suicidality monitoring during titration |
| Peak plasma | About 2 hours after oral dose | Evening dosing aligns peak with sleep period |
| Half-life | About 20 to 40 hours (mean ~30 h); steady state within ~5 days | Reduced clearance in elderly, renal, and hepatic impairment—sedation may linger |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Screen for bipolar disorder history before treating depressive symptoms with antidepressant alone
- Review cardiovascular history (heart failure, recent MI, arrhythmia), seizure history (epilepsy), narrow-angle glaucoma, urinary retention, and fall risk
- Confirm no MAOI within 14 days; reconcile SSRIs and other serotonergic agents via medication reconciliation
- Assess baseline mood, sleep, and safety plan; involve family/caregivers per Medication Guide counseling
Contraindications
- Hypersensitivity to mirtazapine, inactive ingredients, or other dibenzoxepines
- Glaucoma or untreated anatomically narrow angles (pupillary dilation risk)
- Current or past urinary retention
- MAO inhibitors—including linezolid or intravenous methylene blue—unless 14-day washout completed per labeling
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| MAO inhibitors (including linezolid) | Contraindicated—serotonin syndrome risk | Hold mirtazapine; verify 14-day MAOI washout; pharmacist review before restart |
| SSRIs / SNRIs (fluoxetine, sertraline, venlafaxine) | Increased serotonin syndrome risk; overlapping sedation | Coordinate switches with pharmacy; monitor for agitation, hyperreflexia, autonomic instability |
| Other sedatives / CNS depressants | Additive somnolence and psychomotor impairment | Avoid alcohol and benzodiazepine overlap without prescriber intent; compare with trazodone orders |
| QTc-prolonging drugs | Postmarketing QT prolongation and torsades—often with overdose or risk factors | Obtain ECG when symptomatic; hold and clarify new interacting medicines |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or orally disintegrating tablet once daily, preferably in the evening before sleep per labeling.
- Food has minimal effect on absorption—may give without regard to meals unless facility protocol specifies otherwise
- Perform orthostatic blood pressure checks when starting or increasing doses in fall-risk patients
- Counsel that driving and hazardous machinery may be impaired until individual response is known—somnolence led to discontinuation in about 10% of patients in controlled trials
- For orally disintegrating tablets: place on tongue to dissolve; do not crush; PKU patients should note aspartame content per labeling
Observe closely for clinical worsening, suicidality, and unusual behavior when therapy starts and whenever dose changes—especially in young adults. Report emergent anxiety, insomnia, irritability, hostility, akathisia, hypomania, or mania to the prescriber immediately.
Expected therapeutic response
- Gradual improvement in depressive symptoms over 1 to 2 weeks or longer—not immediate
- Improved sleep or appetite may appear before full mood response—do not confuse sedation with recovery
- Stable orthostatic vitals without new confusion or excessive metabolic changes beyond expected therapeutic effect
Red flags — Stop and act
Escalate urgently for suicidality, serotonin syndrome, agranulocytosis, or severe sedation with injury risk.
- New or worsening suicidal ideation, self-harm behavior, or violent impulsivity—immediate prescriber and safety intervention
- Agitation, hallucinations, hyperreflexia, clonus, diaphoresis, or hyperthermia—suspect serotonin syndrome; hold drug and escalate per protocol
- Sore throat, fever, stomatitis, or infection signs with low WBC—suspect agranulocytosis; discontinue mirtazapine per labeling
- Marked oversedation, fall with head injury, or inability to arouse—assess airway and neurologic status
- Acute eye pain or vision changes in patients at risk for angle-closure glaucoma after pupillary dilation
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dry mouth, constipation, urinary retention | Common anticholinergic effects; worse in elderly | Fall precautions, bowel protocol, monitor urine output; notify if retention or ileus |
| Somnolence, dizziness | Very common (somnolence ~54% in U.S. controlled trials) | Bedtime dosing; fall precautions; reassess dose if daytime impairment persists |
| Increased appetite, weight gain | Common; ≥7% body weight gain reported in trials | Monitor weight and glucose in at-risk patients; teach expected metabolic changes |
| Orthostatic hypotension | Significant in volunteer studies; infrequent in depression trials | Orthostatics after dose changes; caution with antihypertensives and dehydration |
| Hyponatremia / SIADH | Serious cases reported with serotonergic antidepressants | Check sodium with confusion or falls; review basic metabolic panel per protocol |
| Elevated transaminases | Clinically significant ALT elevations in ~2% in short-term trials | Monitor liver function tests when hepatic disease present |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose reports include disorientation, drowsiness, impaired memory, and tachycardia. Serious outcomes including fatalities may occur above recommended doses, especially with mixed overdoses. QT prolongation and torsades de pointes have been reported—often with overdose or other QT risk factors.
Critical manifestations
- Marked sedation, confusion, or coma
- Tachycardia, hypotension, or ECG changes including QT prolongation
- Features overlapping serotonin syndrome when other serotonergic agents are involved
Management (nursing priorities)
No specific antidotes for mirtazapine are known per prescribing information. Provide supportive care: airway, breathing, circulation, cardiac monitoring when indicated, and contact local poison control or medical toxicology per facility protocol. Psychiatric follow-up is often appropriate when overdose may be intentional.
Contact local poison control or medical toxicology services per facility protocol when overdose is suspected. Psychiatric follow-up is often appropriate because overdose may be deliberate.
Look-alike / sound-alike and error prevention
- 15 mg vs 30 mg vs 45 mg tablets—independent double-check strength; scored tablets can be split only when pharmacy approves
- Mirtazapine vs amitriptyline—similar sedating antidepressant names; verify correct agent on MAR
- Film-coated tablet vs Remeron SolTab—do not substitute orally disintegrating product without prescriber and pharmacy approval
- Duplicate sedatives—avoid overlapping trazodone, benzodiazepines, or other sedating psychotropics without clear intent
- MAR abbreviations—“mirt” or “Remeron” without milligrams has caused wrong-strength administration; confirm numeric strength every time
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Evening dosing | Give at bedtime when ordered HS—daytime doses increase fall and driving risk unless prescriber specifies otherwise |
| Morning sedation | Next-day somnolence and impaired psychomotor performance reported—assess excessive sleepiness and fall risk |
| Lower doses in elderly | Start at low end of range; confusion and oversedation predominate in geriatric patients per labeling |
| Abrupt stop | Taper gradually—discontinuation syndrome (dizziness, anxiety, abnormal dreams) reported with abrupt stop |
| Ask pharmacy when | Wrong strength dispensed, SSRI added, linezolid ordered, or renal/hepatic dose adjustment needed |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pediatric patients | Not approved for use in pediatric patients per labeling; boxed suicidality warning applies to young patients on antidepressants |
| Young adults (18–24) | Higher suicidality risk versus placebo in short-term antidepressant studies—intensify monitoring at initiation and dose changes |
| Older adults | Conservative dosing; confusion, oversedation, hyponatremia, and falls predominate; clearance reduced per labeling |
| Cardiovascular disease | Not systematically studied post-MI; orthostatic hypotension can worsen ischemic or cerebrovascular disease—use caution |
| Pregnancy / lactation | No reliable signal of major birth defects from published data; untreated depression also carries risk—use pregnancy registry when applicable. Mirtazapine is present in breast milk at low levels; weigh benefits and risks with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Mood, behavior, suicidality, sleep, appetite, and weight at each contact during the first months and after dose changes
- Heart rate, blood pressure, orthostatic symptoms; sodium and hepatic panel when clinically indicated
- Complete blood count when infection signs appear (agranulocytosis risk); mental status and fall events
Document
- Baseline and follow-up safety assessments, family/caregiver education on warning symptoms
- Dose, time, and patient response; any PRN sedative or serotonergic overlap
- Poison-control or toxicology consultation when overdose or serotonin syndrome is suspected
Patient teaching
- Take the dose at bedtime as directed and confirm tablet strength (15, 30, or 45 mg) before each dose
- Antidepressants may increase suicidal thoughts in some people—seek help immediately for worsening depression, agitation, panic, irritability, hostility, or thoughts of self-harm
- Do not stop suddenly without talking to the prescriber; taper gradually to reduce discontinuation symptoms
- Rise slowly from sitting or lying down; avoid alcohol and other sedatives unless approved
- Report excessive sleepiness, falls, sore throat with fever, agitation, sweating, tremor, eye pain, or vision changes
- Increased appetite and weight gain are common—pair with nutrition guidance when needed
- Keep appointments; full antidepressant benefit may take 1 to 2 weeks or longer
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- MAOI used within 14 days (including linezolid) or serotonergic overlap without pharmacy-approved plan
- Active suicidal plan, intentional overdose, or emergent mania/psychosis
- Suspected serotonin syndrome (agitation, hyperreflexia, autonomic instability, hyperthermia)
- Sore throat, fever, or stomatitis with low WBC—hold until prescriber reviews for agranulocytosis
- Unable to arouse, new fall with head injury, or acute angle-closure glaucoma symptoms
- Dispensed strength does not match order (e.g., 30 mg tablet for a 15 mg order)
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Safe mirtazapine nursing hinges on bedtime sedation surveillance, serotonergic reconciliation, and infection screening—not only on mood scores.
1. Check-before-you-give protocol
- Right patient, drug, strength (15/30/45 mg), route, and bedtime time
- MAOI/linezolid history and concurrent SSRI, SNRI, or tramadol documented
- Suicidality screen current when initiating or changing dose
- Fall and orthostatic precautions in place for sedating doses
2. High-alert and safety badge
Sedating antidepressant — falls, serotonin syndrome, agranulocytosisTreat suspected serotonin syndrome or overdose with supportive care and toxicology guidance—no specific antidote exists. Use fall risk assessment when starting or titrating in older adults.
3. Clinical workflow: hold and question rules
- If linezolid is ordered for a patient on mirtazapine, hold mirtazapine and call pharmacy before either drug is given
- If fluoxetine was added without a documented switch plan, hold and call pharmacy—serotonin syndrome risk
- Fever with sore throat and low WBC triggers hold and urgent prescriber notification per labeling
4. Critical teach-back questions
- “What mood or behavior changes should you report right away?” (Worsening depression, suicidal thoughts, agitation, irritability, unusual behavior.)
- “What will you do if you feel very sleepy or dizzy when standing?” (Rise slowly, use fall precautions, call prescriber if impairment persists.)
5. Care coordination
Pharmacist: MAOI washout, SSRI/SNRI switches, renal/hepatic dose adjustment, and serotonergic interaction review
Psychiatry / prescriber: Suicidality escalation, mania activation, and taper plans when stopping therapy
🧠 Quick mental checklist
- Does the tablet strength match the order (15 vs 30 vs 45 mg)?
- Any new SSRI, SNRI, tramadol, or linezolid on the MAR?
- Any suicidal ideation, agitation, or behavioral change since the last dose?
- Orthostatics, sedation, and fall events after last bedtime dose?
- Fever, sore throat, or infection signs that need a WBC check?
Mirtazapine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for mirtazapine with a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), trend interpretation after holding serotonergic drugs, MAOI washout cloze, ordered serotonin-syndrome steps, and a matrix sorting sedation versus interaction versus infection findings—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Mirtazapine 30 mg tablet PO at bedtime — major depressive disorder (14 days)
- Fluoxetine 20 mg PO each morning — started 3 days ago
- Lorazepam 0.5 mg PO BID PRN anxiety — none given in last 24 h
- Linezolid 600 mg PO BID — held pending pharmacy review (ordered yesterday for cellulitis)
- Today 0800 BMP: sodium 128 mmol/L (132 yesterday), potassium 3.8, creatinine 1.1 mg/dL
- CBC: WBC 3.2 × 10⁹/L, ANC 1.4 × 10⁹/L; hemoglobin stable
- Admission sodium 136 mmol/L; no baseline seizure disorder documented
- 76-year-old woman admitted for depression with insomnia and poor intake; fall at home 1 month ago
- History of narrow-angle glaucoma—uses timolol drops; no MAOI use documented
- Prior SSRI trial stopped for nausea; no documented bipolar disorder
- Lives alone; daughter visits daily
- 2200: Given mirtazapine 30 mg; patient asleep within 45 min
- 0600: Restless, picking at sheets; diaphoretic; difficult to redirect
- 0800: HR 118, temp 38.4 °C, BP 98/62; bilateral ankle clonus noted; denies chest pain
- Patient states, “I feel shaky inside and can’t sit still since they added the new antidepressant pill in the morning.”
Answer key & rationale
Frequently asked questions
Why is mirtazapine usually given at bedtime?
Prescribing information recommends a single daily dose preferably in the evening before sleep because somnolence is very common. Sedation may appear before full antidepressant benefit. Counsel patients to avoid driving or hazardous machinery until they know how the drug affects them.
How long must a nurse wait after stopping an MAOI before starting mirtazapine?
At least 14 days must elapse after discontinuing an MAOI antidepressant before starting mirtazapine, and at least 14 days after stopping mirtazapine before starting an MAOI. The same separation applies to linezolid and intravenous methylene blue unless pharmacy and the prescriber direct otherwise per labeling.
What findings suggest serotonin syndrome with mirtazapine?
Labeling lists mental status changes, autonomic instability, neuromuscular signs such as tremor or hyperreflexia, and gastrointestinal symptoms. Risk rises with SSRIs, SNRIs, tramadol, and MAO inhibitors. Hold mirtazapine, stop interacting serotonergic agents, and initiate supportive treatment per protocol.
When should a nurse hold mirtazapine for infection concerns?
If the patient develops sore throat, fever, stomatitis, or other signs of infection with a low white blood cell count, discontinue mirtazapine and monitor closely because agranulocytosis has occurred in premarketing trials. Do not give the dose until the prescriber reviews laboratory results.
Is mirtazapine safe during breastfeeding?
Mirtazapine is present in human milk at low levels with relative infant doses generally under 3% of the maternal weight-adjusted dose in published reports. Most cases report no adverse infant effects, but data on milk production are limited. Weigh benefits and risks with the prescriber.
References
-
U.S. National Library of Medicine. Mirtazapine tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9675333e-3064-c8cb-a4b4-6c74d9a82f17
-
U.S. Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-suicidality-children-and-adolescents-being-treated-antidepressant
-
Drugs and Lactation Database (LactMed). Mirtazapine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM325/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.